LEADER 02588nam 2200493 450 001 9910809803503321 005 20200520144314.0 010 $a1-118-91693-X 010 $a1-118-91694-8 010 $a1-118-91692-1 035 $a(CKB)4330000000007479 035 $a(MiAaPQ)EBC4862949 035 $a(DLC) 2016056137 035 $a(Au-PeEL)EBL4862949 035 $a(CaPaEBR)ebr11386890 035 $a(CaONFJC)MIL1012237 035 $a(OCoLC)965446691 035 $a(PPN)223995754 035 $a(EXLCZ)994330000000007479 100 $a20170615h20172017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aOral bioavailability assessment $ebasics and strategies for drug discovery and development /$fAyman F. El-Kattan 210 1$aHoboken, New Jersey :$cWiley Blackwell,$d2017. 210 4$dİ2017 215 $a1 online resource (455 pages) $cillustrations 225 0 $aWiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods 311 $a1-118-91669-7 320 $aIncludes bibliographical references and index. 327 $aDrug pharmacokinetics and toxicokinetics -- GIT anatomy and physiology and drug oral bioavailability : impact of species differences -- Drug routes of excretion -- Physicochemical and biopharmaceutical properties that affect drug absorption of compounds absorbed by passive diffusion -- Physicochemical and biopharmaceutical factors affecting hepatic/intestinal first pass effect -- Impact of intestinal efflux transporters on oral absorption -- Impact of influx transporters on drug -- Extended Clearance Classification System (ECCS) and its utility in predicting clearance rate determining step in drug discovery -- In vitro and in situ approaches to measure intestinal permeability and efflux transporters -- In silico approaches to predict intestinal permeability -- In vivo preclinical approaches to deconvolute the contribution of first pass effect from oral absorption -- In vitro approaches to assess haptic metabolism and first pass effect -- The utility of ECCS as a roadmap to improve oral bioavailability of new molecular entities : industrial perspective. 606 $aDental pharmacology 615 0$aDental pharmacology. 676 $a615.1/9 700 $aEl-Kattan$b Ayman F.$01668535 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910809803503321 996 $aOral bioavailability assessment$94029200 997 $aUNINA